The single-activated antigen (TNF) α-monoclon antibodies, as a cause of cancer-resistant necrosis (TNF), has demonstrated significant therapeutic effects and multiple advantages in the treatment of the strong straight spinal column (AS). The following are some of the main advantages of the Adam monotherapy for direct spinal disease:
1. Quick and strong control of inflammatory disease: Adam single resistance can quickly and effectively control the inflammatory response of AS. Studies show that there has been a significant decline in C-reaction protein (CRP) during two weeks of treatment, which suggests that single-activation at Adam can rapidly reduce inflammation.
2. Significant improvement in symptoms: A single anti-Adam can significantly improve symptoms such as back pains, morning rigidities, etc. Studies conducted among AS patients in China show that 12 weeks after the use of Adamu monotherapy, improvements in the patient ‘ s back pain rating, BASDAI morning stiff rating, etc. relative to the baseline are significantly higher than in the placebo group.
3. Delaying/preventing structural damage: Long-term studies have shown that the single resistance of Adam effectively slows the radiology of AS patients and reduces the new bone formation, bone damage and bone probity.
4. Improving the quality of life: Adam monotherapy can significantly improve the quality of life of AS patients, including physical, body pain and social functions.
5. Good safety and tolerance: Clinical studies show that the Adam stand alone is good safety and tolerance, that respiratory infections are common over and above the bad events, but to a lesser extent, and that no patients are withdrawn from research due to the bad events.
6. High rates of drug retention: According to data from the RHUMADADA register, the retention rate of the Ardam mono-resistant drug is significantly higher than that of other biological agents, which means that patients tend to use Ardam mono-resistant over time.
7. International authoritative guidelines recommend that, on a rich evidence-based basis, the international authoritative guidelines recommend TNF inhibitors as a first-line option after the failure of traditional treatment for AS patients.
8. Treatment of extra-coalt manifestations: Aluminum stand-up not only improves AS cortex symptoms but also treats extra-cotex manifestations such as grapes and inflammatory enteropathy, which is particularly important for AS patients with these combinations.
9. Deterrence of osteoporosis and fracture of bone structure: Abyssil resistance inhibits the appearance of osteoporosis and fracture of the osteoporosis of ASA patients, which is essential to prevent progression and reduce the risk of disability.
10. All-source antibodies, reducing immunogenicity: A single antibodies at Adam is a whole-source antibodies, reducing the risk of drug removal and reduction in effectiveness by reducing the formation of anti-drugs.
Based on the above, the anti-Adam alone has a significant place in the treatment of direct spinal disease because of its rapid efficacy, significant improvement in symptoms, protection against syndrome, prevention of structural damage, improvement of quality of life and good safety and tolerance. Patients should work closely with doctors to develop individualized treatment programmes.
